Scientist ? Antibody Discovery - Jobs in Jordan

Job Description

OUR PATH TO PRODUCTSA big leap forward in designer biologics to reach untapped biology of the adaptive immune systemThe role of adaptive immunity in autoimmunity and transplantation makes it one of the most prolific areas of biopharmaceutical research. Within both arms of the adaptive immune response ? the humoral response and the cell-mediated response ? aberrant function drives a diverse set of human diseases.Humoral immune mechanisms result in Ig-productionthat is directly pathogenic in a wide range of diseases such as myasthenia gravis, IgA nephropathy and alloantibody transplant rejection.Cell-mediated immunity involving the interactions of immune cellsdirectly causes multiple diseases such as vitiligo, bullous pemphigoid, vasculitis, multiple sclerosis and lupus. Seismic?s lead pipeline programs include two distinct drug product areas that, separately, address both arms of dysregulated adaptive immunity.Humoral immunitydiscovering and developing designer therapeutics to modulate Ig-mediated autoimmunityCell-mediated immunitydesigning biologics to target multiple pathways simultaneously to address diseases of cell-mediated autoimmunityAlan CraneFounder & ChairmanAlan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies. He has served as founder, chairman and/or CEO in building ten Polaris companies. Prior to founding Seismic, Alan co-founded Dyno Therapeutics along with Harvard Professor George Church and scientist Eric Kelsic. Dyno is using insights from computer science and biology to design better viruses for delivery of gene therapies. Prior to Dyno, Alan founded Pandion Therapeutics to focus on tissue-specific immunomodulation for autoimmune disorders and transplantation. In four years from the Polaris seed funding, Pandion became a clinical-stage, public company and was acquired by Merck for $1.85B. Alan?s past portfolio companies have collectively been involved in 12 IPOs and M&A exits. His current and past portfolio includes: (acquired by J&J), (acquired by Merck), (acquired by Otsuka), , , Sirtris Pharmaceuticals (acquired by GSK), Adnexus Therapeutics (acquired by BMS), , , Arsia Therapeutics (acquired by Eagle Pharmaceuticals), and From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline. Momenta was acquired by J&J for $6.5B. Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium?s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding to help fuel the company?s growth and acquiring 19 development stage products. Among these products was Velcade?, which became the main basis of the company?s $9B acquisition by Takeda. Alan received Ernst & Young?s Entrepreneur of the Year award for New England while serving as CEO of Momenta. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children?s Hospital Trust, founder of the Autism Consortium, and president of the board of Gann Academy. Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in biology from Harvard Graduate School of Arts & Sciences and an MBA from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.John Sundy, MD, PhDChief Medical Officer and Head of R&DJohn is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry. His research career has focused on developing novel therapies for patients with inflammatory and fibrotic diseases. Prior to joining Seismic John was the Chief Medical Officer of Pandion Therapeutics, which was acquired by Merck in 2021 for $1.85 billion. He previously was Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences. John led Gilead?s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including Jyselica, which is approved in Europe and Japan for rheumatoid arthritis and/or ulcerative colitis. Before moving to industry, John was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the Phase 1-3 development of Krystexxa which is approved for patients with refractory gout. In addition, he served as Associate Director of the Duke Clinical Research Institute and Director of Duke?s Global Proof of Concept Research Unit Network in the US, Singapore and India. An undergraduate from Bucknell University, John received his medical and scientific education at Drexel University, and residency and fellowship training at Duke. He is a fellow of the American College of Rheumatology, the American Academy of Allergy Asthma and Immunology, and the American College of Physicians. John is an Adjunct Professor of Medicine at Duke University and has clinical privileges in rheumatology at the Duke-affiliated Durham VA Medical Center. He has authored over 100 scientific publications, and also serves on the board of directors of CARRA, the Childhood Arthritis and Rheumatology Research Alliance.Maude Tessier, PhDChief Business OfficerMaude Tessier has over 16 years of company building experience with a multi-disciplinary background in business development, corporate strategy, corporate communications, IP management, and portfolio and program management in public and private biotechnology, pharmaceutical and academic organizations. Prior to joining Seismic, she served as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. At Ikena, she led key company building initiatives, including the negotiation and execution of a $1B+ strategic partnership with BMS, the strategy and execution of the company rebranding and pipeline expansion into targeted oncology, the acquisition of Amplify Medicines, and as part of the executive team, drove core elements of financing activities resulting in over $260M in private and public capital. Previously, Dr. Tessier was Executive Director, Business Development and Licensing at Merck & Co, leading oncology partnering in the Boston innovation hub. She served as Assistant Director, Business Development and Strategic Initiatives at Boston Children?s Hospital. She began her career at Xanthus Pharmaceuticals, a venture-backed oncology biotech company in Cambridge, Mass., where she had key roles in business development and program management of a Phase 3 drug candidate leading to its eventual FDA approval. She holds a BSc in Biochemistry from McGill University and a PhD from the Department of Medical Biophysics at the University of Toronto.Edward Freedman, JDChief Financial OfficerEd has more than 25 years of leadership experience directing finance, legal and operations activities in companies across multiple industries. Ed has served as COO of Pandion Therapeutics as well as in CFO roles at Dyno Therapeutics, Faze Medicines, Kymera Therapeutics, Mana Therapeutics, KSQ Therapeutics, XTuit Pharmaceuticals, Oasys Water and Ensemble Therapeutics. Ed also served as General Counsel of Flagship Ventures (now Flagship Pioneering) and started his legal career at Testa, Hurwitz & Thibeault, LLP. Before going to law school, Ed was an accountant at Arthur Andersen & Co. Ed earned his JD from Boston College Law School and his BSBA in Accounting from Boston Un

Keyskills :